Aurélie Cabannes‐Hamy

Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia

Marie-Émilie Dourthe, Florence Rabian, Karima Yakouben et al. · Leukemia · 2021 · 145 citations

Hematological Malignancy, Lymphoid Neoplasia, Transplantation +10

High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL

Aurélie Cabannes‐Hamy, Éolia Brissot, Thibaut Leguay et al. · Haematologica · 2022 · 42 citations · Full text

B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL

Benjamin Fournier, Estelle Balducci, Nicolas Duployez et al. · Frontiers in Oncology · 2019 · 38 citations · Full text

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study

Patrice Chevallier, Thibault Leguay, Rathana Kim et al. · Blood · 2022 · 32 citations

NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

Mathieu Simonin, Loïc Vasseur, Étienne Lengliné et al. · Blood · 2024 · 30 citations · Full text